RATIONALE: @entity3652 or @entity3390 induced sensorimotor gating deficit, but the underlying neural mechanisms are not completely known. We have previously demonstrated that the @entity5381 ( @entity5381 ) mediated the @entity12781 -induced deficit in prepulse inhibition of the acoustic startle (PPI) in @entity35 . OBJECTIVES: We investigated the involvement of the supramammillary area (SUM) to @entity5381 pathway in @entity73 and @entity146 induced by @entity3390 or @entity3652 in @entity35 and correlated the @entity146 with hippocampal gamma wave increase. MATERIALS AND METHODS: @entity3652 (6 mg/kg, s.c.) or @entity3390 (0.5 mg/kg, i.p.) was administered after infusion of saline or the @entity1246 (A) receptor agonist, @entity6341 (0.25 microg), into the @entity5381 or SUM. Locomotion, PPI, and hippocampal electroencephalogram (EEG) were recorded. RESULTS: @entity3390 or @entity3652 induced @entity73 and @entity146 , accompanied by an increase in hippocampal gamma waves (30-100 Hz). The changes in behavior and gamma waves induced by @entity3652 or @entity3390 were antagonized by pre-infusion of @entity6341 , but not saline, into the SUM or @entity5381 . Infusion of @entity6341 into the SUM alone did not significantly affect PPI, but it suppressed spontaneous locomotor behavior and hippocampal EEG. Infusion of ionotropic @entity2227 receptor antagonists into the @entity5381 did not affect the PPI deficit or the gamma wave increase after @entity3390 . CONCLUSIONS: A non-glutamatergic component of the supramammillo-septal pathway mediates the hyperlocomotion and the deficits in PPI induced by @entity3390 or @entity3652 . Inactivation of the @entity5381 or SUM normalized both the hippocampal gamma waves and the @entity146 ( @entity73 and hyperlocomotion).

The supramammillo-septal-hippocampal pathway mediates sensorimotor gating impairment and hyperlocomotion induced by XXXX and @entity3652 in @entity35 .

@entity6341 :: ('MESH:D009118', 'Chemical') :: ['muscimol'] @entity2227 :: ('CHEBI:29987', 'Chemical') :: ['glutamate'] @entity1246 :: ('MESH:D005680', 'Chemical') :: ['GABA'] @entity146 :: ('MESH:D001523', 'Disease') :: ['behavioral deficits', 'behavioral hyperlocomotion'] @entity12781 :: ('MESH:D010622', 'Chemical') :: ['phencyclidine'] @entity73 :: ('MESH:D003072', 'Disease') :: ['PPI impairment'] @entity5381 :: ('MESH:D061270', 'Disease') :: ['MS', 'medial septum'] @entity3652 :: ('MESH:D007649', 'Chemical') :: ['ketamine', 'Ketamine'] @entity35 :: ('10116', 'Species') :: ['rats'] @entity3390 :: ('MESH:D016291', 'Chemical') :: ['MK-801']
@entity3390 :: (MESH:D016291,Chemical) :: ['MK-801']
